TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22565291

Group type: EXPERIMENTAL
Intervention: Intrapartum antibiotic prophylaxis (10.5% of women received this intervention)
Number of subjects: 8129

Group type: COMPARATOR
Intervention: Preterm delivery
Number of subjects: 8129

Group type: COMPARATOR
Intervention: Low birth weight (<1500 g)
Number of subjects: 8129

Group type: COMPARATOR
Intervention: Meconium-stained amniotic fluid (MSAF)
Number of subjects: 8129

Group type: COMPARATOR
Intervention: First birth
Number of subjects: 8129
Study: 22566312

Group type: EXPERIMENTAL
Intervention: GLP-1 levels in patients with stress hyperglycaemia requiring vasoactive support
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glycaemia levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GLP-1 levels
Number of subjects: 60
Study: 22566420

Group type: EXPERIMENTAL
Intervention: Computer-facilitated screening and provider brief advice (cSBA)
Number of subjects: 2685

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2685
Study: 22566506

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.15-0.30 mg/kg per day in 2 divided oral doses) and prednisone (60 mg per day, tapered off during 1 to 4 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tacrolimus and prednisone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 26
Study: 22566605

Group type: EXPERIMENTAL
Intervention: Decitabine (20 mg/m² intravenously on days 1-10) plus bortezomib (escalated up to the target 1.3 mg/m² on days 5, 8, 12, and 15)
Number of subjects: 19
Study: 22566747

Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (ExQW)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 25000

Group type: EXPERIMENTAL
Intervention: High-adherence insulin
Number of subjects: 25000
Study: 22568777

Group type: EXPERIMENTAL
Intervention: DIGS software insulin dosage adjustments
Number of subjects: 46
Study: 22569039

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22569123

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) 20 Gy with Intrabeam system/Carl Zeiss
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 540
Study: 22570147

Group type: EXPERIMENTAL
Intervention: Efatutazone at doses ranging from 0.10 to 1.15 mg PO twice daily for 6 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Efatutazone at the recommended phase 2 dose of 0.5 mg PO twice daily
Number of subjects: 31
Study: 22571443

Group type: EXPERIMENTAL
Intervention: High-resolution MRI with local anaesthetics injected
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-resolution MRI without local anaesthetics injected
Number of subjects: 18
Study: 22572602

Group type: EXPERIMENTAL
Intervention: Integrated multisector approach (Millennium Villages project)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline levels of MDG-related spending
Number of subjects: 0
Study: 22573483

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Combination therapy of RAAS blockade and diuretics
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Two or more diuretics
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Combination therapy with diuretics and RAAS blockade
Number of subjects: 633
Study: 22574715

Group type: EXPERIMENTAL
Intervention: In-patient treatment program based on physical exercise and a balanced diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group of 15 teenagers
Number of subjects: 32
Study: 22576262

Group type: EXPERIMENTAL
Intervention: New-onset RA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic RA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P gingivalis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anaeroglobus geminatus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prevotella and Leptotrichia species
Number of subjects: 0
Study: 22576338

Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen (irinotecan 180 mg/m² i.v. on day 1, leucovorin 200 mg/m² i.v. on days 1 and 2, 5-FU 400 mg/m² i.v. bolus on days 1 and 2, and 5-FU 600 mg/m² i.v. by ci for 22 h on days 1 and 2, repeated every 2 weeks)
Number of subjects: 50
Study: 22577154

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) treatment
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BCL2L10 knockdown
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Percentage of BCL2L10 expressing cells (assessed by flow cytometry)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Proportion of BCL2L10 positive bone marrow cells
Number of subjects: 77
Study: 22578085

Group type: EXPERIMENTAL
Intervention: EMR-based clinical decision support (CDS)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1092
Study: 22579160

Group type: EXPERIMENTAL
Intervention: Intermittent treatment with tapering and discontinuation of risperidone long-acting injection over 6 weeks, followed by reinstitution of oral risperidone or risperidone long-acting injection upon symptom recurrence.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned, but refers to the absence of continuous treatment after 2 years.
Number of subjects: 33
Study: 22580120

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (54 Gy, 5-fluouracil-based)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Decrease between early (1 h) and late (3 h) SUVmax at 6-week PET/CT
Number of subjects: 91
Study: 22580254

Group type: EXPERIMENTAL
Intervention: Offline fusion of co-registered IVUS and OCT images
Number of subjects: 9
Study: 22580941

Group type: EXPERIMENTAL
Intervention: Reoperation after primary umbilical/epigastric hernia repair
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Reoperation after incisional hernia repair
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Overall recurrence after primary umbilical/epigastric hernia repair
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Overall recurrence after incisional hernia repair
Number of subjects: 902
Study: 22581378

Group type: EXPERIMENTAL
Intervention: Instrumental support
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Support from partners and families
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Racial/ethnic differences in mobilizing support
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Identifying support needs and expectations
Number of subjects: 33
Study: 22581488

Group type: EXPERIMENTAL
Intervention: Formula™ balloon-expandable renal stent
Number of subjects: 100
Study: 22582313

Group type: EXPERIMENTAL
Intervention: Higher individual SES (1-standard deviation increase)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Higher neighborhood SES (1-standard deviation increase)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Higher neighborhood SES (controlling for individual SES)
Number of subjects: 284
Study: 22583155

Group type: EXPERIMENTAL
Intervention: Gantenerumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 22583335

Group type: EXPERIMENTAL
Intervention: Rilonacept (320 mg loading dose followed by 160 mg weekly for up to 1 year)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 8
Study: 22586008

Group type: EXPERIMENTAL
Intervention: Laxative-free computed tomographic colonography (CTC)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 605
Study: 22586182

Group type: EXPERIMENTAL
Intervention: FCR (fludarabine, cyclophosphamide, rituximab)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: (90)YFC (90yttrium ibritumomab tiuxetan added to FCR)
Number of subjects: 73

Group type: COMPARATOR
Intervention: FCR
Number of subjects: 73

Group type: COMPARATOR
Intervention: (90)YFC
Number of subjects: 73
Study: 22586466

Group type: EXPERIMENTAL
Intervention: Overfeeding (+1040 ± 100 kcal/day, 46 ± 1% of energy from fat)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overfeeding
Number of subjects: 40
Study: 22587415

Group type: EXPERIMENTAL
Intervention: LIFEspan Model
Number of subjects: 0
Study: 22587481

Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 22589436

Group type: EXPERIMENTAL
Intervention: Oral minocycline 100 mg twice daily for 6 months
Number of subjects: 5
Study: 22589446

Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in MS patients with optic neuritis
Number of subjects: 192

Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in MS patients without optic neuritis
Number of subjects: 192

Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in NMO patients
Number of subjects: 192

Group type: COMPARATOR
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in LETM patients
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Fourier-domain optical coherence tomography (FD-OCT) measurements in healthy controls
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Correlation between OCT and visual field (VF) findings in NMO/LETM and MS
Number of subjects: 192
Study: 22590502

Group type: EXPERIMENTAL
Intervention: 0.1 mg DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.4 mg DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.8 mg DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DermaVir immunization
Number of subjects: 0
Study: 22591622

Group type: EXPERIMENTAL
Intervention: ASV-CO2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ASV-CO2-O2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressure Support Ventilation
Number of subjects: 15
Study: 22592608

Group type: EXPERIMENTAL
Intervention: Continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of blinatumomab
Number of subjects: 0
Study: 22594355

Group type: EXPERIMENTAL
Intervention: Combination of copeptin and cTnI
Number of subjects: 641

Group type: COMPARATOR
Intervention: cTnI alone
Number of subjects: 641
Study: 22594491

Group type: EXPERIMENTAL
Intervention: GRAZAX(®) (Phleum Pratense, 75,000 SQ-T/2,800 BAU), administered as one tablet daily for at least 4 months before the pollen season and maintained throughout the season.
Number of subjects: 628
Study: 22595848

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy followed by total mesorectal excision
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Oligonucleotide array-based comparative genomic hybridization
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Predictive model for lymph node metastasis
Number of subjects: 95
Study: 22599356

Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal neurostimulation (THN) therapy with the aura6000™ System
Number of subjects: 14
Study: 22605616

Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) 120, 240, 360, and 480 mg BID plus erlotinib 150 mg QD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tivantinib (ARQ 197) 360 mg BID plus erlotinib 150 mg QD
Number of subjects: 32
Study: 22605650

Group type: EXPERIMENTAL
Intervention: Tivantinib 120 mg orally twice daily, then 360 mg twice daily per protocol amendment
Number of subjects: 47
Study: 22605655

Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dersalazine sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene expression analysis
Number of subjects: 0
Study: 22607272

Group type: EXPERIMENTAL
Intervention: Caries experience in first graders
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Caries experience in second graders
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Sealant prevalence in first graders
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Sealant prevalence in second graders
Number of subjects: 485

Group type: COMPARATOR
Intervention: Statistical significance of caries experience
Number of subjects: 485
Study: 22607892

Group type: EXPERIMENTAL
Intervention: Obese women with PCOS (OP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lean women with PCOS (LP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lean controls (LC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Obese controls (OC)
Number of subjects: 60
Study: 22608106

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg BID
Number of subjects: 155
Study: 22608261

Group type: EXPERIMENTAL
Intervention: Individualised accelerated radiotherapy (INDAR) with a mean lung dose (MLD) of 19 Gy, spinal cord 54 Gy, brachial plexus 66 Gy, central structures 74 Gy, total dose between 51 and 69 Gy delivered in 1.5 Gy BID up to 45 Gy followed by 2 Gy QD, starting at the 2nd or 3rd course of chemotherapy
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Individualised accelerated radiotherapy (INDAR)
Number of subjects: 137
Study: 22608338

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily (recommended phase 2 dose)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily (in patients with Val600Glu BRAF-mutant melanoma)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily (in patients with Val600 BRAF-mutant melanoma)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dabrafenib (in patients with melanoma and untreated brain metastases)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Dabrafenib (in patients with BRAF-mutant non-melanoma solid tumours)
Number of subjects: 184
Study: 22609885

Group type: EXPERIMENTAL
Intervention: Pre-transplantation iron chelation
Number of subjects: 0
Study: 22610494

Group type: COMPARATOR
Intervention: Dictation
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Structured documentation
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Free text documentation
Number of subjects: 7000
Study: 22612475

Group type: EXPERIMENTAL
Intervention: Urinary phthalate metabolites (12 phthalate metabolites including MEP, MnBP, MiBP, MBzP, MEHP, MEHHP, MEOHP, MECPP, MiNP, MHiNP, MiONP, MCiOP)
Number of subjects: 555
Study: 22614181

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy after neoadjuvant sunitinib
Number of subjects: 22

Group type: COMPARATOR
Intervention: Open radical nephrectomy for non-metastatic disease
Number of subjects: 22
Study: 22614730

Group type: EXPERIMENTAL
Intervention: Esophageal long-term electrocardiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22614770

Group type: EXPERIMENTAL
Intervention: Early-onset mut patients (n = 21)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Late-onset mut patients (n = 6)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: cblA patients (n = 7)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: cblB patients (n = 6)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: mut patients diagnosed prenatally or by newborn screening (n = 3)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hyperammonemia at diagnosis
Number of subjects: 43

Group type: COMPARATOR
Intervention: Presence of a seizure disorder
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Longitudinal testing (n = 10)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Processing speed
Number of subjects: 43
Study: 22614885

Group type: EXPERIMENTAL
Intervention: cART (nevirapine, 3TC with either zidovudine or stavudine)
Number of subjects: 529
Study: 22615311

Group type: EXPERIMENTAL
Intervention: Two doses of 30-μg 2009 Novartis pH1N1 monovalent vaccine (Fluvirin)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Second vaccination for those lacking seroresponse or seroprotection after first vaccination
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: First vaccination
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Two doses of double-strength pH1N1 vaccine
Number of subjects: 155
Study: 22615340

Group type: EXPERIMENTAL
Intervention: Biological antiplatelet drug responsiveness (specific and aggregation-based assays)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Common cardiovascular risk factors (hypertension, smoking, older age, elevated low-density lipoprotein cholesterol)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Primary endpoint (MACEs)
Number of subjects: 771
Study: 22619284

Group type: EXPERIMENTAL
Intervention: Investigational pump (intrapericardially positioned, continuous-flow centrifugal pump)
Number of subjects: 639

Group type: COMPARATOR
Intervention: Commercially available pump (control group)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Investigational pump
Number of subjects: 639
Study: 22619884

Group type: EXPERIMENTAL
Intervention: Hybridization real time PCR for 23S rRNA gene detection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clarithromycin resistance detection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clarithromycin susceptibility determined by E-test
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Detection of mutation gene A2142G
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Detection of multiple mutations (G2111A, A2115G, A2144G)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Resistance prevalence for other antibiotics
Number of subjects: 200
Study: 22621223

Group type: EXPERIMENTAL
Intervention: Routine pre-/postnatal lactation consultant (LC) support
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Electronic prompts (EP) guiding providers to discuss breastfeeding
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combined intervention (LC+EP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 67
Study: 22621246

Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplementation (fish oil capsules providing 1.14g DHA and 1.56g EPA for 12 weeks)
Number of subjects: 20
Study: 22622425

Group type: EXPERIMENTAL
Intervention: Anti-IL-17 receptor antibody AMG 827
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22622497

Group type: EXPERIMENTAL
Intervention: At-home short daily hemodialysis (6 times per week)
Number of subjects: 291
Study: 22623056

Group type: EXPERIMENTAL
Intervention: GDC-0152
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control samples at 0.0600, 2.00 and 8.00 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GDC-0152 in human plasma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GDC-0152 in whole blood
Number of subjects: 0
Study: 22623715

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: hs-cTnT and hs-cTnI
Number of subjects: 887
Study: 22624038

Group type: EXPERIMENTAL
Intervention: Persistent systemic inflammation in COPD patients
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Non-inflamed COPD patients
Number of subjects: 1755
Study: 22626269

Group type: EXPERIMENTAL
Intervention: MR-guided HIFU ablation (Sonalleve 1.5T; Philips Medical Systems, Vantaa, Finland)
Number of subjects: 11
Study: 22626609

Group type: EXPERIMENTAL
Intervention: Triple therapy (boceprevir, peginterferon, and ribavirin) after 4 weeks of peginterferon and ribavirin for a total treatment duration of 28-48 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon and ribavirin for 48 weeks (control group).
Number of subjects: 0
Study: 22626819

Group type: EXPERIMENTAL
Intervention: Higher BMI (Body Mass Index)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Baseline F(2)-isoprostane
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Intraoperative F(2)-isoprostane
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Intraoperative PAI-1 (plasminogen activator inhibitor-1)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: F(2)-isoprostanes (as a mediator)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: PAI-1
Number of subjects: 445
Study: 22627070

Group type: EXPERIMENTAL
Intervention: Post-polypectomy surveillance colonoscopy
Number of subjects: 902

Group type: COMPARATOR
Intervention: High-volume workload centres
Number of subjects: 902

Group type: COMPARATOR
Intervention: Centres providing written recommendation on surveillance interval
Number of subjects: 902

Group type: COMPARATOR
Intervention: Surveillance examinations performed within the national screening programme
Number of subjects: 902
Study: 22627182

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg with lopinavir/ritonavir 400 mg/100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of pitavastatin with and without lopinavir/ritonavir
Number of subjects: 24
Study: 22627615

Group type: EXPERIMENTAL
Intervention: Reader interpretation of chest radiographs (CXRs) for NCNs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Follow-up recommendations based on CXR interpretation
Number of subjects: 100
Study: 22627678

Group type: EXPERIMENTAL
Intervention: Midostaurin 50-mg twice-daily dose schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin 100-mg twice-daily dose schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin in combination with standard chemotherapy
Number of subjects: 0
Study: 22631877

Group type: EXPERIMENTAL
Intervention: Patient-Centred Rehabilitation Model (PCRM-CI)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 22633255

Group type: EXPERIMENTAL
Intervention: Conventional ovulation induction with clomiphene citrate followed by exogenous gonadotropins
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: First model (age, duration of infertility, insulin/glucose ratio)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Second model (age, duration of infertility, body mass index)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: First model
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Second model
Number of subjects: 108
Study: 22633265

Group type: EXPERIMENTAL
Intervention: GnRH agonists with serum P levels ≥ 2.0 ng/mL
Number of subjects: 2555

Group type: COMPARATOR
Intervention: GnRH agonists with serum P levels <1.5 ng/mL
Number of subjects: 2555

Group type: COMPARATOR
Intervention: GnRH agonists with serum P levels 1.5-1.99 ng/mL
Number of subjects: 2555

Group type: COMPARATOR
Intervention: GnRH antagonists
Number of subjects: 2555